Skip to main content
Premium Trial:

Request an Annual Quote

GVK Renews License for Biomarker Database to FDA

NEW YORK (GenomeWeb News) – Indian contract research organization GVK Bio announced today the extension of its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration.

The GOBIOM database contains the most recent information on all biomarkers reported in various clinical and preclinical studies. In total, it has data on more than 20,000 biomarkers, including biochemical, genomic, imaging, metabolite, cellular, and physiological markers. Also included are multiple data points "comprising experimental, analytical, clinical, and statistical data with their qualifications under different medical interventions," GVK said.

"The collaboration with the US FDA has helped GVK BIO in developing the safety biomarker content in GOBIOM," Sreeni Devidas, vice president of sales and marketing for informatics at GVK, said in a statement. "The interconnectivity between organ toxicities to the drug, dose and population was developed with equal emphasis on its preclinical qualification. Biomarker analysis tools were integrated into the database in a manner that has facilitated the user to make a comparative analysis between the biomarkers of their interest."

The FDA group originally licensed the GOBIOM database in 2007 and renewed it in April 2011.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.